SCHEMBL6824375

SCHEMBL6824375

CC(C)OC(=O)c1ccnc2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
HPGD P15428 3/20 0.47
KDM4E B2RXH2 2/20 0.47
HSD17B10 Q99714 1/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 2/20 0.45
CYP3A4 P08684 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944369 0.89 NSD2 (0.48) ALDH1A1HPGDKDM4EHSD17B10NPC1
SCHEMBL16130518 0.82 PDCD1 (0.51) ALDH1A1HPGDKDM4EHSD17B10NPC1
SCHEMBL827693 0.82 PSMD14 (0.57) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL11816233 0.81 CCR1 (0.45) ALDH1A1HPGDNPC1RAB9AMEN1
SCHEMBL27957255 0.81 KDM5A (0.42) ALDH1A1HPGDKDM4EHSD17B10MEN1
SCHEMBL827639 0.80 MEN1 (0.47) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL3079961 0.79 KDM4E (0.57) ALDH1A1HPGDKDM4EHSD17B10NPC1
SCHEMBL22169485 0.79 LMNA (0.44) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL13100925 0.79 NSD2 (0.46) NPC1RAB9AMEN1KMT2APREP
SCHEMBL29523397 0.78 NUDT1 (0.57) ALDH1A1HPGDKDM4EHSD17B10RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846291-B2 Resist composition, method of forming resist pattern, and new compound TOKYO OHKA KOGYO CO. LTD. (JP) 2014-09-30 US disclosed
US-20120148955-A1 RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, AND NEW COMPOUND TOKYO OHKA KOGYO CO., LTD. (JP) 2012-06-14 US disclosed
WO-2004072046-A2 QUINOLINE DERIVATIVES AND THEIR USE FOR MODULATION OF LXR ACTIVITY CAREX S.A. (FR) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120148955-A1 RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, AND NEW COMPOUND C1R, SLC11A2, RER1 ALDH1A1 2007/4885HPGD 1530/4885KDM4E 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.